Cytokinetics is rumored to be in M&A talks: https://www.reuters.com/markets/deals/cytokinetics-exploring-options-after-receiving-takeover-interest-bloomberg-news-2023-10-31/

[12/27 update] Cytokinetics released positive topline data for SEQUOIA-HCM trial testing their lead compound, aficamten, in patients with obstructive hypertrophic cardiomyopathy
https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-positive-results-sequoia-hcm-pivotal

As background, BMS acquired MyoKardia for $13.1B in 2020 for a comparable drug, mavacamten https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx